Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
PARP inhibitors
Pharma
AZ, GSK make case for broad I-O uses in endometrial cancer
For AstraZeneca's and GSK's PD-(L)1/PARP regimens, the contribution of a PARP drug in a subset of endometrial cancer patients have come into question.
Angus Liu
Mar 18, 2024 11:05am
GSK tees up AstraZeneca rivalry with Jemperli-Zejula combo data
Dec 18, 2023 11:13am
Lynparza fails to improve on Keytruda in first-line lung cancer
Dec 7, 2023 9:21am
Pfizer's Talzenna wins broader prostate cancer nod than AZ rival
Jun 21, 2023 10:45am
FDA sends CRL to Clovis in last-gasp bid for Rubraca nod
Jun 5, 2023 10:20am
ASCO: AZ eyes wider ovarian cancer market with Imfinzi-Lynparza
Jun 3, 2023 8:00am